恒生医疗ETF(513060)盘中涨超1%，冲击3连涨，机构看好创新药BD催化延续

Group 1 - The Hang Seng Healthcare Index (HSHCI) increased by 0.87% as of July 15, 2025, with notable gains from stocks such as Health Road (02587) up 9.58% and BeiGene (06160) up 5.18% [3] - The Hang Seng Healthcare ETF (513060) has seen a 1.01% rise, marking its third consecutive increase, with a latest price of 0.6 yuan [3] - The ETF's trading volume was active, with a turnover of 1.151 billion yuan and a turnover rate of 13.96% [3] Group 2 - The adjustment of the 2025 National Basic Medical Insurance and commercial health insurance drug catalogues officially started on July 11, 2025, with results expected to be announced between October and November 2025 [4] - In the first half of 2025, China's innovative drug license-out transactions reached nearly 66 billion USD, surpassing the total for 2024, indicating strong interest from multinational pharmaceutical companies [4] - Key transaction categories include Antibody-Drug Conjugates (ADC) and bispecific antibodies, with expectations for continued activity in the second half of 2025 [4] Group 3 - The Hang Seng Healthcare ETF's size grew by 196 million yuan over the past week, ranking it in the top third among comparable funds [5] - The ETF's net value has increased by 19.77% over the past two years, with a maximum monthly return of 28.34% since inception [5] - The ETF's Sharpe ratio for the past year is 2.02, indicating strong risk-adjusted returns [5] Group 4 - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [6] - The ETF's tracking error over the past year is 0.060%, the highest tracking precision among comparable funds [6] - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 28.79, indicating a valuation lower than 87.88% of the time over the past three years [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.84% of the index, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [6]